Clinical Trial News and Research

RSS

Lilly and Transition Therapeutics announce licensing and collaboration agreement

Eli Lilly and Company and Transition Therapeutics Inc. has announced that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing.

14 Mar 2008

Is deep-vein thrombosis lurking in your legs?

They kill 300,000 people a year - but most of them could be prevented. They strike more than a million people every year, most of them out of the blue - and half without causing symptoms.

14 Mar 2008

Trial of new procedure that may help emphysema suffers

Researchers at Henry Ford Hospital have announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new option for those suffering with advanced emphysema.

13 Mar 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

Weight loss more effective than intensive insulin therapy for type 2 diabetics

Weight-loss and major lifestyle changes may be more effective than intensive insulin therapy for overweight patients with poorly controlled, insulin-resistant type 2 diabetes, according to a diabetes researcher at UT Southwestern Medical Center.

12 Mar 2008

Postoperative chemotherapy does not improve survival in gastric cancer patients

The use of combination chemotherapy following surgery did not improve survival in patients with gastric cancer, according to a randomized clinical trial published online March 11 in the Journal of the National Cancer Institute .

12 Mar 2008

New cancer research model bridges health disparity gap

The Accelerated Community Oncology Research Network (ACORN), a national oncology clinical trial network, has announced that it is bridging the disparity gap in healthcare to underserved communities by enrolling more than double the national average of African Americans in cancer-related clinical trials.

12 Mar 2008

Blood test for Parkinson's shows promise

A test that profiles molecular biomarkers in blood could become the first accurate diagnostic test for Parkinson's disease, new research shows.

12 Mar 2008

Researchers find treatment for familial cold autoinflammatory syndrome

Dalhousie Medical School dermatologist Dr. Barrie Ross and his colleagues have successfully ended a 20-year quest to find a treatment for Familial Cold Autoinflammatory Syndrome (FCAS).

12 Mar 2008

Anadis licenses antibody technologies from ImmuCell

Anadis Limited, an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation, a biotechnology company headquartered in Portland, Maine, USA.

11 Mar 2008

Weight-loss more effective than intensive insulin therapy for type 2 diabetics, according to expert

11 Mar 2008

Better management of ovarian cancer

The results of a study presented at the Society of Gynecologic Oncology's 39th Annual Meeting on Women's Cancer offer a promising development on the path toward better management of ovarian cancer.

11 Mar 2008

Late treatment with letrozole (Femara) can reduce breast cancer recurrence risk

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.

11 Mar 2008

Femara helps protect against return of breast cancer after completing Tamoxifen therapy

Women may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole tablets) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.

11 Mar 2008

Tackling antimicrobial resistance

Drug resistance is making many diseases increasingly difficult and sometimes impossible to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

11 Mar 2008

Paradoxical Alzheimer's finding may provide better understanding of memory loss

Do you remember the seventh song that played on your radio on the way to work yesterday?

10 Mar 2008

Fugitive cancer cells can be blocked by stopping blood cells that aid them

Cancer cells get a helping hand from platelets, specialized blood cells involved in clotting.

10 Mar 2008

Risks of long-term hormone therapy continue to outweigh benefits

New results from the Women's Health Initiative (WHI) confirm that the health risks of long-term use of combination (estrogen plus progestin) hormone therapy in healthy, postmenopausal women persist even a few years after stopping the drugs and clearly outweigh the benefits.

6 Mar 2008

Cancer risk slightly higher for women in discontinued hormone treatment trial

A follow up study of participants in the Women's Health Initiative (WHI) clinical trial led by a University of North Carolina at Chapel Hill researcher has found that women who were taking the combined hormone therapy of estrogen plus progestin may have an increased risk of cancer since the intervention was stopped, compared to participants in the trial's placebo group.

6 Mar 2008

Bioniche receives fast track for bladder cancer therapy

Bioniche Life Sciences Inc. has announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its therapy for first-line non-muscle-invasive bladder cancer meets the criteria for Fast Track designation.

6 Mar 2008